TG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Rating of "Moderate Buy" by Brokerages

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $26.17.

Several equities research analysts have recently weighed in on TGTX shares. B. Riley increased their target price on shares of TG Therapeutics from $24.00 to $29.00 and gave the company a "buy" rating in a research note on Monday, February 5th. StockNews.com downgraded shares of TG Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, February 24th. HC Wainwright reaffirmed a "buy" rating and issued a $45.00 price target on shares of TG Therapeutics in a research note on Wednesday, February 28th. Finally, The Goldman Sachs Group raised their price target on shares of TG Therapeutics from $12.00 to $13.00 and gave the stock a "neutral" rating in a research note on Thursday, February 29th.

Insider Activity

In other news, Director Laurence N. Charney sold 22,000 shares of the firm's stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total value of $351,340.00. Following the sale, the director now directly owns 215,229 shares in the company, valued at approximately $3,437,207.13. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 9.20% of the company's stock.

Hedge Funds Weigh In On TG Therapeutics

A number of institutional investors have recently bought and sold shares of TGTX. Los Angeles Capital Management LLC increased its holdings in shares of TG Therapeutics by 55.8% during the 1st quarter. Los Angeles Capital Management LLC now owns 76,616 shares of the biopharmaceutical company's stock valued at $1,165,000 after purchasing an additional 27,437 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of TG Therapeutics by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 13,670,944 shares of the biopharmaceutical company's stock valued at $233,500,000 after purchasing an additional 199,770 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of TG Therapeutics by 1.4% during the 4th quarter. Wellington Management Group LLP now owns 3,139,764 shares of the biopharmaceutical company's stock valued at $53,627,000 after purchasing an additional 43,290 shares in the last quarter. Eventide Asset Management LLC purchased a new position in shares of TG Therapeutics during the 4th quarter valued at approximately $7,506,000. Finally, FIL Ltd purchased a new position in shares of TG Therapeutics during the 4th quarter valued at approximately $738,000. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Price Performance

TG Therapeutics stock traded down $0.60 during mid-day trading on Friday, reaching $14.16. 3,880,506 shares of the company's stock traded hands, compared to its average volume of 2,259,096. The company has a market cap of $2.19 billion, a price-to-earnings ratio of 708.35 and a beta of 2.30. The stock has a 50 day moving average of $15.21 and a two-hundred day moving average of $13.80. The company has a quick ratio of 5.18, a current ratio of 5.92 and a debt-to-equity ratio of 0.62. TG Therapeutics has a 12-month low of $6.46 and a 12-month high of $35.67.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.03. The company had revenue of $43.97 million for the quarter, compared to the consensus estimate of $40.06 million. TG Therapeutics had a net margin of 5.42% and a return on equity of 12.89%. During the same quarter in the prior year, the firm earned ($0.39) earnings per share. Equities analysts forecast that TG Therapeutics will post -0.12 earnings per share for the current year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.